<DOC>
	<DOCNO>NCT01424345</DOCNO>
	<brief_summary>The purpose study demonstrate whether outcome benefit serial ImmuKnow assay management de novo renal transplant recipient .</brief_summary>
	<brief_title>The Role ImmuKnowÂ® Management Immunosuppressants Renal Transplant Patient</brief_title>
	<detailed_description>Background : The management renal transplant recipient challenge keep delicate balance immunosuppression avoid either infection ( overimmunosuppression ) , rejection ( under-immunosuppression ) . Conventional clinical parameter adequate enough . ImmuKnow ( Cylex Inc , Columbia , MD ) FDA-cleared assay detection cell mediate immune response population undergo immunosuppressive therapy organ transplant . There limited retrospective study discuss effectiveness ImmuKnow assay . There prospective head-to-head trial show benefit periodic ImmuKnow test . Objective : To demonstrate whether outcome benefit serial ImmuKnow assay de novo renal transplant recipient Patients Methods : A prospective , randomize , pilot , control 12-month study compare outcomes 2 cohort de novo renal transplant patient conduct . The outcome investigate include combine infection rate ( primary end-point ) , separate infection rate episodes , acute rejection rate episode , quality life , graft patient survival ( secondary end-points ) . Biopsy transplant kidney use confirm rejection whenever possible . Among study cohort , patient ' immunosuppressant adjust accord result serial ImmuKnow assay besides use conventional clinical parameter ; whereas among control cohort patient ' immunosuppressant adjust accord conventional clinical parameter . Expected Results : At end study able learn whether study cohort patient le infection , less acute rejection , good allograft function , good quality life , good graft patient survival .</detailed_description>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>1 . De novo kidney transplant patient eligible kidney transplant accord UNOS criterion agree participate study . 2 . Patients sex age 18 80 year . Any patient know immunocompromised disease ( e.g . patient AIDS ) leukocytosis ( &gt; 15,000u/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Immune monitoring</keyword>
</DOC>